Johnson & Johnson announced Monday that it has completed its acquisition of Novira Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of chronic hepatitis B, for an undisclosed price.
The acquisition includes Novira’s portfolio of novel antivirals, New Brunswick-based Johnson & Johnson said in a news release. Novira will now be part of the Infectious Diseases & Vaccines Therapeutic Area of the Janssen Pharmaceutical Companies of Johnson & Johnson.
“We are exploring several approaches in pursuit of a functional cure for this insidious disease. Bringing together NVR 3-778 with our own internal discoveries we will leverage our vast experience in viral diseases to develop potentially transformational medicines for HBV patients,” William N. Hait, global head, Janssen Research & Development LLC, said in a prepared statement.